Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

被引:0
|
作者
Waede, Mie [1 ,2 ,3 ]
Voss, Lasse F. [4 ]
Kingo, Christina [1 ,2 ,3 ]
Moeller, Jesper B. [3 ,5 ]
Elkjaer, Maria L. [1 ,2 ,3 ,6 ]
Illes, Zsolt [1 ,2 ,3 ,7 ]
机构
[1] Odense Univ Hosp, Dept Neurol, Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Univ Southern Denmark, Dept Mol Med, Odense, Denmark
[4] Tech Univ Denmark, Dept Hlth Technol, Sect Expt & Translat Immunol, Lyngby, Denmark
[5] Univ Southern Denmark, Danish Inst Adv Study, Odense, Denmark
[6] Univ Hamburg, Inst Computat Syst Biol, Hamburg, Germany
[7] Univ Southern Denmark, BRIDGE Brain Res Interdisciplinary Guided Excellen, Odense, Denmark
来源
关键词
NATURAL-KILLER-CELLS; T-CELLS; CHEMOKINE RECEPTORS; NK CELLS; CEREBROSPINAL-FLUID; ACTIVATION; EXPRESSION; RITUXIMAB; CD38; INFLAMMATION;
D O I
10.1002/acn3.52182
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Anti-CD20 therapy is a highly effective treatment for multiple scle-rosis (MS). In this study, we investigated MS-related changes in peripheralblood mononuclear cell (PBMC) subsets compared to healthy controls and lon-gitudinal changes related to the treatment.Methods: Multicolor spectral flowcytometry analysis was performed on 78 samples to characterize disease- andtreatment-related PBMC clusters. Blood samples from MS patients were col-lected at baseline and up to 8 months post-treatment, with three collectionpoints after treatment initiation. Unsupervised clustering tools and manual gat-ing were applied to identify subclusters of interest and quantify changes. Results: B cells were depleted from the periphery after anti-CD20 treatment asexpected, and we observed an isolated acute, transitory drop in the proportionof natural killer (NK) and NKT cells among the main populations of PBMC(P=0.03,P=0.004). Major affected PBMC subpopulations were cytotoxicimmune cells (NK, NKT, and CD8(+)T cells), and we observed a higher propor-tion of cytotoxic cells with reduced brain-homing ability and a higher regula-tory function as a long-term anti-CD20-related effect. Additionally, anti-CD20therapy altered distributions of memory CD8(+)T cells and reduced exhaustionmarkers in both CD4(+)and CD8(+)T cells.Interpretation: The findings of thisstudy elucidate phenotypic clusters of NK and CD8(+)T cells, which have previ-ously been underexplored in the context of anti-CD20 therapy. Phenotypicmodifications towards a more regulatory and controlled phenotype suggest thatthese subpopulations may play a critical and previously unrecognized role inmediating the therapeutic efficacy of anti-CD20 treatments.
引用
收藏
页码:2657 / 2672
页数:16
相关论文
共 50 条
  • [1] Development of anti-CD20 therapy for multiple sclerosis
    Bartok, Beatrix
    Silverman, Gregg J. J.
    EXPERIMENTAL CELL RESEARCH, 2011, 317 (09) : 1312 - 1318
  • [2] Tumefactive onset of multiple sclerosis treated with anti-CD20 therapy: a case series
    Imperatore, Y.
    Vecchio, D.
    Virgilio, E.
    Naldi, P.
    Cantello, R.
    Comi, C.
    Bianco, A.
    Stecco, A.
    Costantini, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 494 - 495
  • [3] Vertebral Inflammatory Changes in Multiple Sclerosis Patients Treated with Anti-CD20 Drugs
    Kilgo, W. A.
    Minto, E.
    Soltys, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 103 - 103
  • [4] Multiple Sclerosis and disability progression in anti-CD20 treated patients: a radiomics approach
    Panzera, Ivan
    Fiscone, Cristiana
    Tonon, Caterina
    Lugaresi, Alessandra
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 561 - 561
  • [5] Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
    Heming, Michael
    Wiendl, Heinz
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (06)
  • [6] Risk factors for developing lymphopenia and hypogammaglobulinemia in anti-cd20 treated patients with multiple sclerosis
    Vollmer, B.
    Vollmer, T.
    Corboy, J.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 304 - 304
  • [7] Immunological Response to COVID-19 Vaccine Boosters in Multiple Sclerosis Patients Treated with anti-CD20 Therapy
    De Oliveira, Antonia
    Lei, Joyce
    Liu, Jiayuan
    Roche, Morgan
    Lin, Jerry
    Alfonso, Roberto
    Sadiq, Saud
    NEUROLOGY, 2023, 100 (17)
  • [8] Influence of Body Mass Index on B Lymphocyte Repopulation in Multiple Sclerosis Patients Treated with Anti-CD20 Therapy
    Loeffler, Jacob
    Han, May
    NEUROLOGY, 2023, 100 (17)
  • [9] Longitudinal COVID-19 immune trajectories in autoimmune patients on anti-CD20 therapy
    Bazzi, S.
    Maguire, C.
    Holay, N.
    Geltman, J.
    Hurley, K.
    Ehrlich, L.
    Triplett, T.
    Melamed, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 230 - 230
  • [10] Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis
    Vollmer, Brandi
    Nair, Kavita
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    NEUROLOGY, 2019, 92 (15)